RNAZ (TransCode Therapeutics) Short Ratio


RNAZ TransCode Therapeutics Inc RNAZ
32 GF Score
Price $7.52
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RNAZ
32GF Score
TransCode Therapeutics Inc RNAZ
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
32GF Score

Get the complete analysis for RNAZ

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.52
Price